Xspray Pharma
Develops improved cancer drugs (PKIs) using a patented amorphous formulation technology.
XSPRAY | ST
Overview
Corporate Details
- ISIN(s):
- SE0009973563 (+3 more)
- LEI:
- 549300NGRQCNZ3X4L157
- Country:
- Sweden
- Address:
- Scheeles väg 2, 171 65 Solna
- Website:
- https://xspraypharma.com/
- Sector:
- Manufacturing
Description
Xspray Pharma is a pharmaceutical company that utilizes its patented technology platform to develop improved versions of marketed drugs, primarily focusing on Protein Kinase Inhibitors (PKIs) for cancer treatment. The company's core innovation lies in its ability to create stable, amorphous (non-crystalline) formulations of active pharmaceutical ingredients. This unique approach enables the development of product candidates that can bypass the secondary patents of original crystalline drugs, facilitating market entry upon the expiration of the primary substance patent. Xspray Pharma's products are designed to offer clinical benefits for patients compared to the original branded drugs and their subsequent generic equivalents.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-02-12 08:16 |
Rättelse: FDA har registrerat Xspray Pharmas kompletterade ansökan för Dasynoc®…
|
Swedish | 46.2 KB | ||
| 2024-02-12 07:59 |
FDA Accepts Xpray Pharma’s NDA-resubmission for Dasynoc® – PDUFA Date set to 31…
|
English | 45.0 KB | ||
| 2024-02-07 17:30 |
Xspray Pharma appoints Michael af Winklerfelt as acting CFO
|
English | 43.6 KB | ||
| 2024-02-07 17:30 |
Xspray Pharma utser Michael af Winklerfelt till tillförordnad CFO
|
Swedish | 44.0 KB | ||
| 2023-12-29 08:00 |
Nytt antal aktier och röster i Xspray Pharma
|
Swedish | 40.3 KB | ||
| 2023-12-29 08:00 |
New number of shares and votes in Xspray Pharma
|
English | 41.0 KB | ||
| 2023-12-01 11:45 |
Xspray Pharma raises SEK 92.3 million through warrants TO5
|
English | 45.2 KB | ||
| 2023-12-01 11:45 |
Xspray Pharma tillförs 92,3 MSEK genom teckningsoptioner TO5
|
Swedish | 45.1 KB | ||
| 2023-11-09 13:33 |
Xspray Pharma erhåller avsiktsförklaringar från storägare och nyckelpersoner av…
|
Swedish | 45.1 KB | ||
| 2023-11-09 13:33 |
Xspray Pharma’s large shareholders and key individuals declare their intent to …
|
English | 45.2 KB | ||
| 2023-11-08 08:00 | Swedish | 673.8 KB | |||
| 2023-11-08 08:00 | English | 724.3 KB | |||
| 2023-10-24 13:40 |
Xspray Pharma’s Nomination Committee for the Annual General Meeting 2024
|
English | 44.6 KB | ||
| 2023-10-24 13:40 |
Xspray Pharmas valberedning inför årsstämman 2024
|
Swedish | 44.1 KB | ||
| 2023-09-11 16:44 |
Xspray Pharma ingår förlikningsavtal med Bristol Myers Squibb i patenttvisten o…
|
Swedish | 45.3 KB |
Automate Your Workflow. Get a real-time feed of all Xspray Pharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Xspray Pharma
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Xspray Pharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-01-10 | Anders Ekblom | Other | Buy | 168,000 | 4,998,000.00 SEK |
| 2024-06-04 | Ribbskottet AB Anders Bladh | Other | Buy | 1,958 | 145,655.62 SEK |
| 2024-06-03 | Anders Bladh, Ribbskottet | Other | Buy | 3,042 | 225,077.58 SEK |
| 2024-05-29 | Per Andersson | Other | Buy | 51,749 | 489,545.54 SEK |
| 2024-05-27 | Per Andersson | Other | Sell | 9,950 | 687,545.00 SEK |
| 2024-05-16 | Anders Bladh | Other | Buy | 10,000 | 503,500.00 SEK |
| 2024-05-02 | Maris Hartmanis | Other | Other | 2,385 | 95,400.00 SEK |
| 2024-05-02 | Christine Lind | Other | Other | 666 | 26,640.00 SEK |
| 2024-05-02 | Anders Ekblom | Other | Other | 500 | 20,000.00 SEK |
| 2024-03-05 | Robert Molander | Other | Buy | 5,000 | 20,000.00 USD |
Peer Companies
